Open-label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adult Liver Transplant Recipients with Genotype 1 Hepatitis C Virus (HCV) Infection (CORAL-I).
Phase of Trial: Phase II
Latest Information Update: 10 Jun 2019
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms CORAL-I
- Sponsors AbbVie
- 28 Jul 2017 Status changed from active, no longer recruiting to completed.
- 09 Feb 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Jul 2017.
- 18 Jan 2017 This trial has been completed in Spain as per European Clinical Trials Database record.